DIA Europe is more than a traditional meeting. It’s a chance to learn, engage, and grow as a healthcare professional alongside thousands of cross-functional collaborative leaders.

British drugmaker AstraZeneca (AZ) has missed another opportunity to secure a share in the lucrative immunoncology market: a Phase III trial combining durvalumab with tremelimumab missed the survival endpoint.

BioEcho Life Sciences develops novel kits for the isolation and processing of DNA and RNA. The new EchoCLEAN CleanUp kits for rapid single-step purification of RNA or DNA samples with removal of any residual denaturating salts or organic solvents increase the reliability in PCR and NGS analysis.

LSP and Sofinnova Ventures co-led the financing of the Amsterdam-based gene therapy specialist  XyloCor Therapeutics.

For two days, Lille was the place to be for partnering in early stage innovation. On December 5th, Europe’s leading tech transfer event BioFIT wrapped up, recording a record number of participants.

Uncommon mutations in three genes in estrogen receptor positive breast cancer have a negative impact on disease prognosis reports a team of British and Australian researchers in Nature Communications. 


GlaxoSmithKline said it will pay $75 per share in cash to take over US oncology player Tesaro, whose FDA-approved DNA repair blocker nirparib (Zejula) made only US$166m in sales in Q1-3/2018.

Janssen affiliate Cilag GmbH International has licenced argenx’ anti-CD70 antibody cusatuzumab (ARGX-110) for US$300m upfront.

Forbion, a European life science venture capital firm, today announces that Carlo Incerti, M.D., will be joining Forbion as Operating Partner, effective 1st January 2019.

Swiss, French and German researchers have unraveled a molecular pathway that might be useful to prevent Graft-versus-Host Disease (GVHD) in leukemic recipients of blood stem cell transplants.